

Upper airway · 2: Bronchiectasis, cystic fibrosis and sinusitis

M R Loebinger,¹ D Bilton,² R Wilson¹

¹ Host Defence Unit, Royal Brompton Hospital, London, UK;
² Cystic Fibrosis Unit, Royal Brompton Hospital, London, UK

Correspondence to:
Dr R Wilson, Host Defence Unit,
Royal Brompton Hospital,
Sydney Street, London SW3
6NP, UK; r.wilson@rbht.nhs.uk

Received 7 May 2009
Accepted 31 May 2009

ABSTRACT

The nose and paranasal sinuses are contiguous with the lower respiratory tract. Patients with bronchiectasis and cystic fibrosis commonly have sinonasal disease, which is thought to have the same aetiology and pathophysiology as the chronic lung disease. Despite this, the conditions are rarely considered together and there is very little literature on the treatment of sinonasal disease in bronchiectasis. In addition to being a common cause of comorbidity, there is evidence suggesting that sinonasal disease may directly influence the bronchial condition. This article reviews sinonasal disease in bronchiectasis and cystic fibrosis and addresses the possible interactions between the health and disease of the upper and lower airways.

The upper respiratory tract comprising the nose and paranasal sinuses has the same mucosal lining as the lower airways, and both compartments are involved together in health and disease. The relevance of this “single airway” concept has been demonstrated with asthma, allergic rhinitis and nasal polyposis, but it may be similarly useful in chronic infective respiratory conditions. Investigation of the upper airway may be useful as a marker of disease in the less accessible lower airway. In addition, treatment of one compartment may have benefits throughout the whole respiratory tract. Improvements in sinus health have been reflected in improved lower airway disease in asthma.¹ This has not been studied in bronchiectasis or cystic fibrosis, but the implications are similar in that viral and bacterial infections can pass from one to the other.

Mucociliary clearance is an important first-line defence of both the upper and lower respiratory tracts. The nose, sinuses, trachea and bronchi are lined by ciliated and mucus-producing cells which form the mucociliary escalator and trap inhaled matter and propel it to the nasopharynx, where it can be expectorated or swallowed. Mucus transport depends on both the integrity and function of the ciliated epithelium and the properties of the mucus. The cilia beat at a rate of between 12 and 16 strokes per second in a consistent direction and in a coordinated fashion. The periciliary fluid layer is of the required depth equalling the vertical height of a cilium, and the mucus must be of suitable rheology for transport.

Impaired sinonasal clearance leads to stasis of secretions, which are only removed from the nasal cavity by blowing or postnasal drip. This makes the host prone to bacterial infection which results in neutrophilic inflammation leading to chronic rhinosinusitis. Bacterial products and neutrophilic

inflammation damage the epithelium and stimulate excess mucus production, and mucosal swelling blocks the sinus ostia, further impairing mucus clearance. Bacterial infection and damage caused by the host inflammatory response interact, perpetuating the disease process, and in chronic rhinosinusitis the disease can become independent of continued bacterial infection. Similarly, impaired clearance from the lower airways leads to chronic respiratory infection and inflammation that has been termed a “vicious circle”, leading to the progression of bronchiectasis.² It is therefore not surprising that bronchiectasis and sinusitis often coexist.

Other important host defences in the upper respiratory tract include immunoglobulins, defensins and antibacterial components of the mucus such as lysozyme. The defences can be impaired by primary or secondary abnormalities (table 1). The upper respiratory tract is often exposed first to an infectious agent and to higher concentrations of inhaled matter and, for this reason, the initial symptoms may come from this site and may be more severe.

SINONASAL DISEASE

The nasal cavity conditions the air we breathe, and it also acts as a first line of defence by impacting unwanted particles on the mucosa and excluding them from the lower respiratory tract. The paranasal sinuses (frontal, maxillary, ethmoid and sphenoid) are air-filled spaces within the skull. They reduce the weight of the skull and humidify and heat inhaled air. These cavities connect with the nose via small orifices called ostia, which may become blocked by swelling of inflamed mucosa.

Rhinosinusitis is defined as inflammation of the nose and paranasal sinuses. Diagnostic criteria include the presence of two or more symptoms which should include one of nasal obstruction/congestion or anterior/posterior rhinorrhoea. Other symptoms include anosmia and facial pain or pressure. The patient's symptom score can describe severity of disease on a visual analogue scale.³ Patients should also have evidence of rhinosinusitis on examination with polyps, mucopurulent discharge or oedema around the middle meatus on nasendoscopy or mucosal changes evident on the CT scan.⁴

Acute rhinosinusitis consists of symptoms lasting <12 weeks, and can be subdivided into acute viral rhinosinusitis with a duration of <10 days and acute non-viral rhinosinusitis with symptoms lasting between 10 days and 12 weeks.

Chronic rhinosinusitis is defined by persistent symptoms lasting >12 weeks. It can be subdivided

Table 1 Host defence abnormalities leading to chronic bacterial infection of the upper and lower airways

Host defence	Primary	Secondary
Cilia	Kartagener's syndrome Primary ciliary dyskinesia	Viral infection Cigarette smoke
Mucus	Young's syndrome	Viral infection Cigarette smoke Allergy
Periciliary fluid	Cystic fibrosis	Air conditioning Dehydration HIV
Antibacterial	Common variable immunodeficiency	
Unknown	Idiopathic bronchiectasis	Panbronchiolitis Yellow nail syndrome Ulcerative colitis

by the presence or absence of nasal polyps. Nasal polyposis is a chronic inflammatory disease of the nose and sinus mucosa. The polyps occur when the oedematous lining of the nasal mucosa becomes dependent, causing some obstruction of the nasal cavity. They can be found throughout the upper respiratory tract but are most commonly located around the ostiomeatal complex. Nasal polyposis is frequently associated with asthma, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and aspirin sensitivity. Polyps are classified as: 0, no polyps; 1, mild (not reaching the upper edge of the inferior turbinate); 2, moderate (between the upper and lower edges of the inferior turbinate); and 3, severe (reaching the lower edge of the inferior turbinate).⁵ The aetiology of chronic rhinosinusitis may be infective or non-infective. The pathogenic role played by bacteria in chronic rhinosinusitis is unknown. On the one hand they may be an important stimulus of neutrophilic inflammation, whereas they can also be seen as passengers taking advantage of the inflammatory milieu created by poor drainage from obstructed ostia. The role of anaerobic bacteria in these circumstances is also uncertain. It is also unknown whether the different sinonasal pathologies are independent diseases or part of a spectrum with nasal polyps, the result of chronic rhinosinusitis which arises from an episode of acute rhinosinusitis. Complications of chronic sinusitis include mucocele formation which are cysts lined by respiratory epithelium. They occur in the sinus cavities and can cause erosion of the surrounding bony structures. Less commonly, orbital and intracranial spread of infection, osteomyelitis and cavernous sinus thrombosis may occur.

Between 2.7% and 6.6% of the population are thought to have chronic rhinosinusitis.⁶ There is an increased incidence in patients with chronic inflammatory lower respiratory disease and associations have been demonstrated with asthma and chronic obstructive pulmonary disease (COPD),⁷ in addition to bronchiectasis. Chronic rhinosinusitis can impact heavily on quality of life with significant impairments noted on both general and specific health status instruments. One study showed that patients with chronic rhinosinusitis had more general body pain and worse social functioning than those with COPD or heart failure.⁸ Despite this, there is no clear correlation between the severity of sinonasal disease and quality of life.⁹

BRONCHIECTASIS

Bronchiectasis is defined as the abnormal dilation of the bronchi due to the loss of elastic and muscular components of the wall thought to be due to destruction by enzymes such as collagenase and elastase from neutrophils. Clinically, it is

Table 2 Common causes of bronchiectasis and chronic rhinosinusitis

Disorder	Examples	Prevalence of chronic rhinosinusitis	References
Idiopathic		45–84%	11, 12
Abnormal mucociliary clearance	PCD CF Young's syndrome	Up to 100%	13 14 15
Immunocompromise	HIV Common variable hypogammaglobulinaemia	Up to 100%	16
Postinfective	Tuberculosis Non-tuberculous mycobacteria (eg, MAC) Whooping cough Measles	50%	11
Excessive immune response	ABPA GvHD Inflammatory bowel disease	40–90% Depends on severity of bronchiectasis	17
Mechanical obstruction	Tumour Foreign body Lymphadenopathy	Infrequent	

ABPA, allergic bronchopulmonary aspergillosis; CF, cystic fibrosis; GvHD, graft versus host disease; HIV, human immunodeficiency virus; MAC, mycobacterium avium complex; PCD, primary ciliary dyskinesia.

characterised by excess mucus production and recurrent lower respiratory tract infections. It is the end result of several different aetiologies (table 2). The most common causes of bronchiectasis are idiopathic and postinfective damage.^{10–11} Chronic rhinosinusitis occurs in 45–84% of patients with idiopathic bronchiectasis^{11–12} and is less common in patients with postinfective bronchiectasis where an acute infection has damaged the bronchial tree.¹¹ It is almost universal, and often more severe, when the sinusitis and bronchiectasis share a common aetiology due to the host defence abnormalities listed in table 1. These conditions include ciliary defects in PCD and mucous abnormalities in CF.

Primary ciliary dyskinesia (PCD)

Each ciliated epithelial cell contains 50–200 motile cilia responsible for the removal of mucus and attached foreign material. The cilia are 5–7 µm in length and consist of nine peripheral microtubule pairs with dynein arms and radial spokes and two central microtubules. The cilia have a forward extended stroke which contacts the viscous outer mucous layer, followed by a reverse stroke where it returns back to the starting point within the watery periciliary layer.¹⁸ PCD is an autosomal recessive condition whereby ciliary motility is absent or severely impaired leading to sinusitis, otitis media, glue ear, chronic bronchitis, bronchiectasis and male infertility. The association of situs inversus characterises Kartagener's syndrome. There are many different ultrastructural ciliary defects, with abnormalities in the dynein arms most frequent. Patients have congested noses from birth and often have difficulty breast feeding due to the inability to nose breathe. This history should alert the paediatrician to the need for cilia investigation.¹⁹ A common physical sign is pooling of mucus in the floor of the nasal cavity.

Young's syndrome

Young's syndrome is characterised by bronchiectasis, chronic rhinosinusitis and male infertility. Ciliary function is found to be normal and clearance is impaired because the mucus is

viscous. There is an association with mercury poisoning in childhood from teething powders and treatment of worm infections.²⁰ Diagnosis is made on exclusion of CF and PCD, or the characteristic finding of obstruction by waxy material at the caput during scrotal exploration for infertility.

Cystic fibrosis (CF)

CF is a single gene autosomal recessive condition characterised by a defect in the CF transmembrane conductance regulator gene product that leads to abnormalities of ion flux at the epithelial surface. The increased sodium absorption leads to periciliary liquid depletion and abnormal mucus movement. Clinically, patients progress to chronic respiratory failure caused by bacterial infections and have pancreatic insufficiency.

CLINICAL ASSESSMENT OF SINONASAL DISEASE IN BRONCHIECTASIS

Assessment of mucociliary clearance

Nasal mucociliary clearance can be tested by a saccharin method whereby a small saccharin particle is placed on the medial side of the inferior turbinate and the time taken to experience the taste recorded, with abnormal values typically >20 min.²¹ More objective measures include the use of colloid particles labelled with technetium-99 and a gamma camera for detection.²²

The structure and function of the cilia is assessed following a nasal brush biopsy, whereby a cytology brush (or equivalent) is used to scrape epithelial cells from the inferior turbinate. Ciliary beat pattern can then be assessed under a light microscope, and the frequency measured by the interruption of a light beam with a photometer.²³ Electron microscopy is used to assess ciliary ultrastructure and to determine orientation.²⁴

The above tests are relatively simple and minimally invasive and, in addition to giving information regarding the mucociliary escalator in the nose, can be extrapolated to the lower respiratory tract. Studies have shown a correlation between the saccharin test results and the pulmonary clearance of an inhaled radiolabelled isotope, and nasal and tracheal beat frequencies have also been shown to be correlated.²⁵

Expired nitric oxide levels may be useful in the assessment of a patient with bronchiectasis. They can be used as a screening tool for PCD.²⁶ In PCD the nitric oxide levels are low, particularly in the nose, possibly due to the reduced activity of nitric oxide synthase.²⁷ This contrasts with non-PCD bronchiectasis where the bronchial levels are higher than in healthy controls. It is important to note that reduced nitric oxide levels are also found in CF²⁸ and both acute and chronic rhinosinusitis,²⁹ but not to the same degree.

Assessment of upper airway

Assessment of the upper airway begins with a review of the symptoms experienced by the patient and an assessment of their severity. The amount and type of discharge, and any facial pain or smell disturbance should be recorded. The degree of nasal obstruction is usually also a subjective measurement, although nasal peak flow can provide an objective measure and other techniques such as rhinomanometry and acoustic rhinometry may be available in some centres.³

Anterior rhinoscopy is required for all patients with chronic nasal disease but may miss small polyps.³ Endoscopy significantly increases the detection of nasal polyps. Radiography of the sinuses can be misleading and, if needed, CT is the imaging modality of choice.³⁰ Nevertheless, approximately one-third of the population have abnormal CT scans so it should not be used

as a primary investigation in rhinosinusitis but in cases of failure of treatment, preoperatively and for complications of sinonasal disease.³¹ Mucosal changes at the ostiomeatal complex or in the sinuses are most commonly seen on CT scans. The Lund-Mackay scoring system scores from 0 to 2 depending on the absence, partial or complete opacification of each sinus.³²

SINONASAL DISEASE IN NON-CF BRONCHIECTASIS

In a Japanese study, 5% of patients with chronic rhinosinusitis were found to have bronchiectasis whereas 45% of patients with idiopathic bronchiectasis had chronic rhinosinusitis.¹² In a UK study, 84% of patients with idiopathic bronchiectasis and 50% of those with postinfective bronchiectasis had chronic rhinosinusitis.¹¹ The major symptoms include anterior and posterior rhinorrhoea, anosmia and nasal obstruction. Nasal polyps occur in up to 40%.³³ *Staphylococcus aureus*, coagulase negative staphylococcus and anaerobic and Gram-negative bacteria are the most frequent upper airway microbes in bronchiectasis.³⁴ Sinonasal disease is universal in PCD and Young's syndrome. Characteristic radiological findings include poorly developed frontal sinuses in PCD.

SINONASAL DISEASE IN CF

Almost every patient with CF has nasal and paranasal sinus disease.¹⁴ Furthermore, heterozygote CF carriers appear to have an increased incidence of sinonasal disease.³⁵ The main symptoms include nasal obstruction, rhinorrhoea, headache and anosmia. Despite this, fewer than 10% of patients with CF typically report significant symptoms.³⁶ This is probably because they have come to accept the symptoms as "normal".

Abnormalities in endoscopic examinations are almost always found and consist of turbinate congestion in 88% and nasal polyposis in one-third of patients.^{37, 38} Histologically, the polyps in CF are different from those in asthma with a lack of dense eosinophilic infiltrate and the preponderance of acid mucin in the glands of CF polyps.^{39, 40} Characteristic CT changes in CF include bulging of the lateral nasal wall, demineralisation of the uncinate process and hypoplasia of the paranasal sinuses.³⁷ Repeat CT scans are not, however, useful in following response to treatments.⁴¹ Sinus cultures in patients with CF are mostly positive with *S aureus* and *Haemophilus influenzae* prevalent in the younger age group and *Pseudomonas aeruginosa* important in older patients.⁴² Other positive cultures include anaerobes and other microbes commonly seen in lower respiratory tract infections. In addition, fungi were isolated from the sinuses in up to one-third of patients with CF undergoing endoscopic sinus surgery.⁴² The importance of fungi in chronic rhinosinusitis is unknown, however an IgE-mediated inflammatory response may occur. Allergic fungal sinusitis was diagnosed in 6.7% of the patients with CF, which is the same incidence as in chronic rhinosinusitis in the general population.⁴²

The incidence of polyposis is greater in patients with $\Delta F 508$ mutations.⁴³ There are no associations between the different sinonasal manifestations and severity of CF.⁴³ Interestingly, children with nasal polyps generally have less severe lung function parameters which has been speculated to be due to a proliferative airway repair mechanism.¹⁴ Complications of sinonasal disease (eg, mucocoeles) in CF are much rarer than in the general population.

MANAGEMENT

There are few randomised controlled trials (RCTs) of the management of chronic rhinosinusitis, and the evidence base is

particularly poor in patients with concurrent CF or bronchiectasis. Initial therapy should be medical with the aim to relieve symptoms, improve quality of life and avoid disease complications. Chronic rhinosinusitis often responds incompletely to treatment, which is usually continued long term.⁴

Medical

Common medical treatments include saline irrigation, antibiotics, topical or systemic steroids, decongestants, antihistamines (which may help with superadded allergic symptoms) and N-acetylcysteine.

Improved drainage

Saline irrigation may help to clear secretions and nasal crustings. This can be with a simple saline nasal spray (eg, Sterimar) or more vigorous douching (eg, Sinu-rinse). Applications can be repeated several times per day to improve symptoms and before other topical treatments, such as steroids, to improve exposure to the drug by the clearance of secretions. Douching is a safe and inexpensive treatment and has been shown to improve symptoms of chronic rhinosinusitis.⁴⁴ The saline may also be hypertonic, which can lead to an osmotic mucosal decongestant effect and may assist mucus clearance. Topical decongestants can be used to relieve symptoms of blockage and facial congestion. They should only be used for short periods to avoid rhinitis medicamentosa.⁴⁵ They can be used before application of topical corticosteroids when the nose is very blocked to improve mucosal exposure.

Steroids

The use of topical nasal steroids in chronic rhinosinusitis has been associated with improvements in both symptoms and objective measures in most randomised controlled studies.^{46–47} There is no evidence for the use of systemic corticosteroids in these patients. In patients who also have nasal polyps, topical steroids have also been shown to reduce polyp size and symptoms.⁴⁸ Treatment with a 2-week course of systemic corticosteroids in this group has improved symptoms and polyp size compared with placebo.⁴⁹ Topical nasal steroids were evaluated in a small RCT of patients with CF and nasal polyps with a reduction in polyp size, judged endoscopically, and an improvement of symptoms. There was no long-term follow-up in this study.⁵⁰ Adopting an “upside down” head position for 3 min can increase exposure to the topical steroid. This has been shown to improve objective measures of benefit.⁵¹

Antibiotics

Topical ointments (eg, Bactroban (mupirocin) and Naseptin (chlorhexidine hydrochloride + neomycin sulphate)) can be helpful when there is vestibulitis and crusting, however there are no studies supporting their clinical effectiveness. There are also limited data supporting the use of systemic antibiotics in chronic rhinosinusitis. Short-term antibiotics (2 weeks) can be used for acute exacerbations. There has been an increased use of systemic macrolide antibiotics for their anti-inflammatory properties for a variety of chronic inflammatory conditions including bronchiectasis, CF, asthma and COPD.⁵² In particular, there has been a substantial improvement in the prognosis of patients with diffuse panbronchiolitis with the use of macrolides.⁵³ In chronic rhinosinusitis, roxithromycin was trialled for 3 months in an RCT and demonstrated improvements in a variety of indices including symptom scores and endoscopy appearances.⁵⁴ Long-term clarithromycin has also been shown to

reduce lavage fluid markers of inflammation.⁵⁵ Macrolides are thought to reduce inflammatory cytokines (eg, interleukin 8, tumour necrosis factor α), inflammatory cell recruitment and free radical production.^{56–59} They also have been shown to improve ciliary motility⁶⁰ and reduce biofilm production.⁶¹ The macrolides have not yet been specifically studied in patients with CF or bronchiectasis with chronic rhinosinusitis.

Other agents

The topical mucolytic, dornase alfa, has been assessed in two RCTs in the postoperative management of sinonasal disease in patients with CF. Both studies found some improvement in endoscopic appearance and symptoms.^{62–63} N-acetylcysteine is also commonly used in chronic rhinosinusitis, but there is no strong evidence of benefit. There are no RCTs for the use of antileukotrienes in chronic rhinosinusitis, although they have shown some benefit in a subgroup of patients with nasal polyps and asthma.⁶⁴ Antihistamines may be useful in patients with superadded allergic symptoms.⁶⁵ The development of nasal nebulisers (Pari, USA) may lead to future therapies—such as hypertonic saline, DNase and antibiotics—being delivered by this route if carefully controlled studies show benefit.

Surgery

The majority of sinus surgery is now performed endoscopically with the aim of improving drainage. This includes sinus washout, increasing the size of the ostia and sinus scrapes to remove hypertrophied mucosa. The improvement in endoscopic surgery has removed the need for more invasive operations such as the removal of diseased maxillary tissue in the Caldwell-Luc operation.

Endoscopic sinus surgery is generally reserved for patients who do not respond to medical treatment. Endoscopic sinus surgery is well tolerated in patients with CF,⁶⁶ however the lack of symptomatic complaints and the disparity between CT findings and clinical disease in this population makes patient selection difficult. Sinus surgery has been shown to reduce symptoms in patients with CF,^{67–68} but there is a lack of evidence suggesting a long-term improvement, particularly with respect to further hospitalisation or lung function parameters.^{68–69} Some authors have suggested persistent nasal obstruction, particularly when demonstrated anatomically, severe symptoms and a correlation between pulmonary exacerbations and sinus symptoms as possible markers of suitable patients.⁷⁰

Table 3 Consideration of sinonasal disease in bronchiectasis

Importance of upper airway	Value of upper airway assessment
Morbidity attached to upper airways disease	Reduction in inflammation may improve quality of life
Similar mucosal surfaces and inflammatory response	Potential marker of lower airway disease Potential site for future research to assess drug responses Treatment may reduce lower respiratory inflammation
Paranasal sinuses and nose may act as reservoir for respiratory pathogens	Pseudomonas eradication regimens may require sinonasal elimination Treatment of sinonasal disease may reduce frequency of lower respiratory infection Treatment for lung transplant patients may reduce recolonisation of transplanted lung

INTERACTION BETWEEN UPPER AND LOWER AIRWAYS

Sinonasal disease is associated with significant morbidity in patients with chronic respiratory disease. However, there is increasing evidence that it should not be considered in isolation and that it can also significantly impact on lower respiratory health (table 3). Most research has been performed in asthma. In these patients there is evidence that inflammation in nasal polyposis is similar to that in the lower respiratory tract with eosinophilic inflammation and IgE production, suggesting that the two conditions are different manifestations of the same disease.⁷¹ There are also data suggesting that the severity of sinonasal disease correlates with the severity of asthma.⁷² Similarly, a study in children with CF showed a correlation between the severity of sinus and pulmonary disease.⁷³ Treatment of the sinonasal condition in asthma can also improve the lower respiratory tract disease. In patients with nasal polyps, treatment with functional endoscopic sinus surgery led to an improvement of asthma symptoms and peak expiratory flow rates in addition to the upper airway parameters.⁷⁴

In bronchiectasis it is also likely that chronic rhinosinusitis will impact on the chronic lower respiratory infections. Chronic sinus inflammation can remodel the upper airways to become a reservoir for opportunistic infections that can descend into the lower respiratory tract. Supporting this hypothesis are studies which showed the same bacterial clones inhabiting both the upper and lower respiratory tracts. A recent study used molecular typing of *S aureus* and *P aeruginosa* in both nasal lavage and expectorated sputum samples to show a high concordance of identical strains.⁷⁵ This confirmed previous studies which had showed similar results from more invasive sampling methods.^{76–77} One of these studies described a temporal relationship, with younger CF patients developing only sinus infections while older patients had evidence of both upper and lower respiratory tract colonisation suggesting a likely migration of organisms from the upper respiratory tract.⁷⁸ Infection of the bronchial tree may be easier to eradicate with systemic and topical antibiotics, whereas poor access to and drainage from the paranasal sinuses may lead to them acting as a “sump” for reinfection after the antibiotic course has finished.

The importance of these findings has not yet been translated into routine clinical practice. It is possible that future care will involve the early detection of upper airway bacterial colonisation and aggressive management to prevent lower respiratory tract infections. *P aeruginosa* eradication protocols may involve treatment of the sinuses to improve success.

There is also a potential role for detection and treatment of the upper airways in lung transplantation. It is known that persistent rhinosinusitis can impact on respiratory morbidity following lung transplantation. One study typed lower respiratory *P aeruginosa* isolates from patients with CF before and after lung transplantation and showed colonisation of the transplanted lung with the same *P aeruginosa* organism after a few months, suggesting that the upper airways are a reservoir for reinfection.⁷⁹ Another group looked at treatment of transplant patients with maxillary sinus surgery and repeat sinus lavages. A reduction in the number of lower respiratory tract infection was found in the treatment group.⁸⁰

SUMMARY

There is increasing evidence that the “single airway” model is an important concept in chronic respiratory disease. This model has gained wide acceptance for the treatment of asthma and rhinitis, however it is clear that the common aetiology and

pathophysiology of sinonasal and respiratory disease also makes this important in bronchiectasis. Appreciation and treatment of concomitant sinonasal disease may improve lower respiratory health and reduce persistent infection and inflammation in the bronchiectatic airway.

Competing interests: None.

Provenance and peer review: Commissioned; not externally peer reviewed.

REFERENCES

1. Rachelefsky GS, Katz RM, Siegel SC. Chronic sinus disease with associated reactive airway disease in children. *Pediatrics* 1984;**73**:526–9.
2. Cole PJ. A new look at the pathogenesis and management of persistent bronchial sepsis: a vicious circle hypothesis and its logical therapeutic connotations. In: Davies RJ, ed. *Strategies for the management of chronic bacterial sepsis*. Oxford: Medicine Publishing Foundation, 1984:1–20.
3. Thomas M, Yawn BP, Price D, et al. EPOS primary care guidelines: European position paper on the primary care, diagnosis and management of rhinosinusitis and nasal polyps 2007 – a summary. *Prim Care Respir J* 2008;**17**:79–89.
4. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. *Clin Exp Allergy* 2008;**38**:260–75.
5. Lildholdt T, Rundcrantz H, Lindqvist N. Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide. *Clin Otolaryngol Allied Sci* 1995;**20**:26–30.
6. Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. *Laryngoscope* 2003;**113**:1199–205.
7. Montemery P, Svensson C, Adelroth E, et al. Prevalence of nasal symptoms and their relation to self-reported asthma and chronic bronchitis/emphysema. *Eur Respir J* 2001;**17**:596–603.
8. Gliklich RE, Metson R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. *Otolaryngol Head Neck Surg* 1995;**113**:104–9.
9. Radenne F, Lamblin C, Vandezande LM, et al. Quality of life in nasal polyposis. *J Allergy Clin Immunol* 1999;**104**:79–84.
10. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. *Am J Respir Crit Care Med* 2000;**162**:1277–84.
11. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. *Respir Med* 2007;**101**:1163–70.
12. Shirahata Y. [Correlation between upper airway tract and lower airway tract in the break down of sinobronchiectasis]. *Nippon Jibiinkoka Gakkai Kaiho* 1990;**93**:1991–8.
13. Greenstone M, Rutman A, Dewar A, et al. Primary ciliary dyskinesia: cytological and clinical features. *Q J Med* 1988;**67**:405–23.
14. Robertson JM, Friedman EM, Rubin BK. Nasal and sinus disease in cystic fibrosis. *Paediatr Respir Rev* 2008;**9**:213–9.
15. Greenstone MA, Rutman A, Hendry WF, et al. Ciliary function in Young's syndrome. *Thorax* 1988;**43**:153–4.
16. Bondioni MP, Duse M, Plebani A, et al. Pulmonary and sinusal changes in 45 patients with primary immunodeficiencies: computed tomography evaluation. *J Comput Assist Tomogr* 2007;**31**:620–8.
17. Shah A, Panchal N, Agarwal AK. Concomitant allergic bronchopulmonary aspergillosis and allergic Aspergillus sinusitis: a review of an uncommon association. *Clin Exp Allergy* 2001;**31**:1896–905.
18. Antunes MB, Cohen NA. Mucociliary clearance—a critical upper airway host defense mechanism and methods of assessment. *Curr Opin Allergy Clin Immunol* 2007;**7**:5–10.
19. Bush A, Cole P, Hariri M, et al. Primary ciliary dyskinesia: diagnosis and standards of care. *Eur Respir J* 1998;**12**:982–8.
20. Hendry WF, A'Hern RP, Cole PJ. Was Young's syndrome caused by exposure to mercury in childhood? *BMJ* 1993;**307**:1579–82.
21. Rutland J, Cole PJ. Nasal mucociliary clearance and ciliary beat frequency in cystic fibrosis compared with sinusitis and bronchiectasis. *Thorax* 1981;**36**:654–8.
22. De Boeck K, Proesmans M, Mortelmans L, et al. Mucociliary transport using 99mTc-albumin colloid: a reliable screening test for primary ciliary dyskinesia. *Thorax* 2005;**60**:414–7.
23. Rutland J, Griffin W, Cole P. Nasal brushing and measurement of ciliary beat frequency. An in vitro method for evaluating pharmacologic effects on human cilia. *Chest* 1981;**80**:865–7.
24. Rutland J, Dewar A, Cox T, et al. Nasal brushing for the study of ciliary ultrastructure. *J Clin Pathol* 1982;**35**:357–9.
25. Andersen I, Camner P, Jensen PL, et al. A comparison of nasal and tracheobronchial clearance. *Arch Environ Health* 1974;**29**:290–3.
26. Wodehouse T, Kharitonov SA, Mackay IS, et al. Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia. *Eur Respir J* 2003;**21**:43–7.
27. Narang I, Ersu R, Wilson NM, et al. Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance. *Thorax* 2002;**57**:586–9.
28. Grasmann H, Michler E, Wallot M, et al. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. *Pediatr Pulmonol* 1997;**24**:173–7.
29. Maniscalco M, Sofia M, Pelaia G. Nitric oxide in upper airways inflammatory diseases. *Inflamm Res* 2007;**56**:58–69.

30. **Iinuma T**, Hirota Y, Kase Y. Radio-opacity of the paranasal sinuses. Conventional views and CT. *Rhinology* 1994;**32**:134–6.
31. **Fokkens W**, Lund V, Bachert C, *et al*. EAAI position paper on rhinosinusitis and nasal polyps executive summary. *Allergy* 2005;**60**:583–601.
32. **Lund VJ**, Mackay IS. Staging in rhinosinusitis. *Rhinology* 1993;**31**:183–4.
33. **Guilemany JM**, Alobid I, Angrill J, *et al*. The impact of bronchiectasis associated to sinonasal disease on quality of life. *Respir Med* 2006;**100**:1997–2003.
34. **Philpott CM**, McKiernan DC. Bronchiectasis and sino-nasal disease: a review. *J Laryngol Otol* 2008;**122**:11–5.
35. **Wang X**, Kim J, McWilliams R, *et al*. Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation. *Arch Otolaryngol Head Neck Surg* 2005;**131**:237–40.
36. **King VV**. Upper respiratory disease, sinusitis, and polyposis. *Clin Rev Allergy* 1991;**9**:143–57.
37. **Coste A**, Gilain L, Roger G, *et al*. Endoscopic and CT-scan evaluation of rhinosinusitis in cystic fibrosis. *Rhinology* 1995;**33**:152–6.
38. **Brihaye P**, Jorissen M, Clement PA. Chronic rhinosinusitis in cystic fibrosis (mucoviscidosis). *Acta Otorhinolaryngol Belg* 1997;**51**:323–37.
39. **Oppenheimer EH**, Rosenstein BJ. Differential pathology of nasal polyps in cystic fibrosis and atopy. *Lab Invest* 1979;**40**:445–9.
40. **Beju D**, Meek WD, Kramer JC. The ultrastructure of the nasal polyps in patients with and without cystic fibrosis. *J Submicrosc Cytol Pathol* 2004;**36**:155–65.
41. **McMurphy AB**, Morris C, Roberts DB, *et al*. The usefulness of computed tomography scans in cystic fibrosis patients with chronic sinusitis. *Am J Rhinol* 2007;**21**:706–10.
42. **Wise SK**, Kingdom TT, McKean L, *et al*. Presence of fungus in sinus cultures of cystic fibrosis patients. *Am J Rhinol* 2005;**19**:47–51.
43. **Sakano E**, Ribeiro AF, Barth L, *et al*. Nasal and paranasal sinus endoscopy, computed tomography and microbiology of upper airways and the correlations with genotype and severity of cystic fibrosis. *Int J Pediatr Otorhinolaryngol* 2007;**71**:41–50.
44. **Heatley DG**, McConnell KE, Kille TL, *et al*. Nasal irrigation for the alleviation of sinonasal symptoms. *Otolaryngol Head Neck Surg* 2001;**125**:44–8.
45. **Scadding GK**. Rhinitis medicamentosa. *Clin Exp Allergy* 1995;**25**:391–4.
46. **Sykes DA**, Wilson R, Chan KL, *et al*. Relative importance of antibiotic and improved clearance in topical treatment of chronic mucopurulent rhinosinusitis. A controlled study. *Lancet* 1986;**2**:359–60.
47. **Lund VJ**, Black JH, Szabo LZ, *et al*. Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients. *Rhinology* 2004;**42**:57–62.
48. **Holopainen E**, Grahne B, Malmberg H, *et al*. Budesonide in the treatment of nasal polyposis. *Eur J Respir Dis Suppl* 1982;**122**:221–8.
49. **Hissaria P**, Smith W, Wormald PJ, *et al*. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. *J Allergy Clin Immunol* 2006;**118**:128–33.
50. **Hadfield PJ**, Rowe-Jones JM, Mackay IS. A prospective treatment trial of nasal polyps in adults with cystic fibrosis. *Rhinology* 2000;**38**:63–5.
51. **Chalton R**, Mackay I, Wilson R, *et al*. Double blind, placebo controlled trial of betamethasone nasal drops for nasal polyposis. *BMJ (Clin Res Ed)* 1985;**291**:788.
52. **Loebinger MR**, Wilson R. Pharmacotherapy for bronchiectasis. *Expert Opin Pharmacother* 2007;**8**:3183–93.
53. **Kudoh S**, Uetake T, Hagiwara K, *et al*. [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. *Nihon Kyobu Shikkan Gakkai Zasshi* 1987;**25**:632–42.
54. **Cervin A**, Wallwork B. Anti-inflammatory effects of macrolide antibiotics in the treatment of chronic rhinosinusitis. *Otolaryngol Clin North Am* 2005;**38**:1339–50.
55. **Cervin A**, Wallwork B, Mackay-Sim A, *et al*. Effects of long-term clarithromycin treatment on lavage-fluid markers of inflammation in chronic rhinosinusitis. *Clin Physiol Funct Imaging* 2009;**29**:136–42.
56. **Nakamura H**, Fujishima S, Inoue T, *et al*. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. *Eur Respir J* 1999;**13**:1371–9.
57. **Anderson R**. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. *J Infect Dis* 1989;**159**:966–73.
58. **Schultz MJ**, Speelman P, Zaat S, *et al*. Erythromycin inhibits tumor necrosis factor alpha and interleukin 6 production induced by heat-killed *Streptococcus pneumoniae* in whole blood. *Antimicrob Agents Chemother* 1998;**42**:1605–9.
59. **Ivetic Tkalecic V**, Bosnjak B, Hrvacic B, *et al*. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. *Eur J Pharmacol* 2006;**539**:131–8.
60. **Yalcin E**, Kiper N, Ozcelik U, *et al*. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. *J Clin Pharm Ther* 2006;**31**:49–55.
61. **Cervin A**, Wallwork B. Macrolide therapy of chronic rhinosinusitis. *Rhinology* 2007;**45**:259–67.
62. **Cimmino M**, Nardone M, Cavaliere M, *et al*. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease. *Arch Otolaryngol Head Neck Surg* 2005;**131**:1097–101.
63. **Raynor EM**, Butler A, Guill M, *et al*. Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis. *Arch Otolaryngol Head Neck Surg* 2000;**126**:581–3.
64. **Ragab S**, Parikh A, Darby YC, *et al*. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. *Clin Exp Allergy* 2001;**31**:1385–91.
65. **Canonica GW**, Tarantini F, Compalati E, *et al*. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. *Allergy* 2007;**62**:359–66.
66. **Lamberty JM**, Rubin BK. The management of anaesthesia for patients with cystic fibrosis. *Anaesthesia* 1985;**40**:448–59.
67. **Jones JW**, Parsons DS, Cuyler JP. The results of functional endoscopic sinus (FES) surgery on the symptoms of patients with cystic fibrosis. *Int J Pediatr Otorhinolaryngol* 1993;**28**:25–32.
68. **Nishioka GJ**, Barbero GJ, Konig P, *et al*. Symptom outcome after functional endoscopic sinus surgery in patients with cystic fibrosis: a prospective study. *Otolaryngol Head Neck Surg* 1995;**113**:440–5.
69. **Jarrett WA**, Militsakh O, Anstad M, *et al*. Endoscopic sinus surgery in cystic fibrosis: effects on pulmonary function and ideal body weight. *Ear Nose Throat J* 2004;**83**:118–21.
70. **Nishioka GJ**, Cook PR, McKinsey JP, *et al*. Paranasal sinus computed tomography scan findings in patients with cystic fibrosis. *Otolaryngol Head Neck Surg* 1996;**114**:394–9.
71. **Bugten V**, Nordgard S, Romundstad P, *et al*. Chronic rhinosinusitis and nasal polyposis; indicia of heterogeneity. *Rhinology* 2008;**46**:40–4.
72. **Ponte EV**, Franco R, Nascimento HF, *et al*. Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis. *Allergy* 2008;**63**:564–9.
73. **Friedman EM**, Stewart M. An assessment of sinus quality of life and pulmonary function in children with cystic fibrosis. *Am J Rhinol* 2006;**20**:568–72.
74. **Ehnhage A**, Olsson P, Kolbeck KG, *et al*. Functional endoscopic sinus surgery improved asthma symptoms as well as PEFR and olfaction in patients with nasal polyposis. *Allergy* 2009;**64**:762–9.
75. **Mainz JG**, Naehrich L, Schien M, *et al*. Concordant genotype of upper and lower airways *P aeruginosa* and *S aureus* isolates in cystic fibrosis. *Thorax* 2009;**64**:535–40.
76. **Dosanjh A**, Lakhani S, Elashoff D, *et al*. A comparison of microbiologic flora of the sinuses and airway among cystic fibrosis patients with maxillary antrastomies. *Pediatr Transplant* 2000;**4**:182–5.
77. **Moss RB**, King VV. Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery. *Arch Otolaryngol Head Neck Surg* 1995;**121**:566–72.
78. **Roby BB**, McNamara J, Finkelstein M, *et al*. Sinus surgery in cystic fibrosis patients: comparison of sinus and lower airway cultures. *Int J Pediatr Otorhinolaryngol* 2008;**72**:1365–9.
79. **Walter S**, Gudowius P, Bosshammer J, *et al*. Epidemiology of chronic *Pseudomonas aeruginosa* infections in the airways of lung transplant recipients with cystic fibrosis. *Thorax* 1997;**52**:318–21.
80. **Lewiston N**, King V, Umetsu D, *et al*. Cystic fibrosis patients who have undergone heart-lung transplantation benefit from maxillary sinus antrastomy and repeated sinus lavage. *Transplant Proc* 1991;**23**:1207–8.